Hurricane season is accompanied by an uptick in infectious diseases associated with environmental and water exposures.
The broad host range and natural reassortment of the influenza virus has played an instrumental role in previous pandemics, and the virus is poised for future large-scale outbreaks.
With evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.
The federal government is working to provide greater access to testing and treatment.
Gonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.
Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
The key is using the right dose on the right patient at the right time.
The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.
Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
A rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Guest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."
Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.
Regarding new-onset seizures in the general population, there was not a statistically significant variance in the risk of experiencing seizures between those who received the vaccine and those who got a placebo.
This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.
Gonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Demystifying clinical data for treating invasive AmpC-harboring Enterobacterales.
A food for thought as an ambulatory antibiotic stewardship initiative.
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Hepatitis B virus vaccination shown to to significantly improve survival rates for patients with chronic hepatitis C, nonalcoholic liver disease, and liver cirrhosis.